| Pharmaceutical Information |
| Drug Name |
Alcaftadine |
| Drug ID |
BADD_D00058 |
| Description |
Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010. |
| Indications and Usage |
For the prevention of itching associated with allergic conjunctivitis. |
| Marketing Status |
approved |
| ATC Code |
S01GX11 |
| DrugBank ID |
DB06766
|
| KEGG ID |
D06552
|
| MeSH ID |
C557708
|
| PubChem ID |
19371515
|
| TTD Drug ID |
D0O7JW
|
| NDC Product Code |
65089-0063; 58602-605; 42973-204; 14501-0020; 12502-5263; 0023-4290; 0023-4291 |
| UNII |
7Z8O94ECSX
|
| Synonyms |
alcaftadine |
|
| Chemical Information |
| Molecular Formula |
C19H21N3O |
| CAS Registry Number |
147084-10-4 |
| SMILES |
CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
